Eli Lilly & Co. has synthesized fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.

Medshine Discovery Inc. has disclosed fused quinazoline compounds acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of solid tumors.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has described pyrazole-substituted cyclopentanol ester derivatives acting as CDK2/cyclin E1 and CDK2/cyclin A2 inhibitors reported to be useful for the treatment of cancer.

Viscient Biosciences LLC has divulged tryptanthrin derivatives acting as indoleamine 2,3-dioxygenase 2 (IDO-2) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.

Serpin Pharma LLC has identified serpin peptide derivatives acting as pro-low-density lipoprotein receptor-related protein 1 (LRP-1) agonists reported to be useful for the treatment of acute lung injury, eosinophilic esophagitis, viral infection, and acute and neuropathic pain, among others.

Zenal Pharmachem LLC has synthesized novel aryl azo pyrazole compounds reported to be useful for the treatment of infections.

Siteone Therapeutics Inc. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Xinthera Inc. has disclosed tricyclic poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Tsinghua University has described non-structural protein 3 (nsp3; PL-pro) (SARS-CoV) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.

Nippon Shinyaku Co. Ltd. has divulged discoidin domain-containing receptor 1 (DDR1) inhibitors reported to be useful for the treatment of nephritis.